Home  »  Stocks to Invest   »  Amarin Corporation plc (AMRN) Could Be On The Verg...

Amarin Corporation plc (AMRN) Could Be On The Verge Of A Correction Soon?

Vascepa, Amarin Corporation plc (AMRN) flagship drug, has been approved for European commercialization. Vascepa will be marketed in the European Union as Vazkepa and given to patients with high stroke and heart attack risk to reduce their risks. This medicine is prescribed to people with elevated triglycerides who take statins.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


Amarin’s stock did not rise strongly following the approval news since this event was expected and was predicted in February 2021.

Nevertheless, Vazkepa is the only therapy of its kind currently approved in Europe. The European Union’s leading cause of death is cardiovascular disease, and a company like Amarin can leverage this opportunity to significantly expand Vascepa’s overseas sales.

One should note that Amarin Corporation plc (AMRN) intends to launch Vascepa in Asia, mainly in China and Hong Kong, in 2021.

Amarin Corporation continues to struggle with competition from generics. The Amarin Corporation plc lost the case in court last year and failed to stop competing drugs with Vascepa properties from entering the market. As a result, AMRN shares dropped significantly. 

Consequently, Amarin Corporation has so far had an influential position in the commercialization of Vascepa only in Europe. As Amarin claims that its Vascepa has a lower price than generics, it intends to compete in other markets’ quality and price.

Moving now on to this publicly-traded company’s trading performance, we will explore the past, current, and future Amarin Corporation (AMRN) trends. Within the last week, AMRN stock gained 7.44%, while over the past one-month period, the stock gained 2.99%. AMRN stock rose 29.37% throughout the last quarter. The stock has been increasing by 53.71% within the last six months and 55.25% in the past year. AMRN Stock’s year-to-date (YTD) price performance is now positive at 26.99%.

Leave a Comment

Your email address will not be published. Required fields are marked *

Most Popular

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Posts

Biotech Stocks to Buy for Sep-2021

Biotechnology (biotech) refers to the use of microbes and cellular biology in health-related research and development. It is not just therapies that biotechnology companies develop.

635

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam